An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

855 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-12-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To analyze the change in International Prostate Symptom Score (IPSS) and serum prostate-specific antigen (PSA) level from baseline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia

NCT02058368

Prostatic Hyperplasia

COMPLETED PHASE3

This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples

NCT01957189

Prostatic Hyperplasia

COMPLETED PHASE1

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

NCT00090103

Prostatic Hyperplasia

COMPLETED PHASE3

(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia

NCT05236634

Benign Prostatic Hyperplasia

UNKNOWN NA

Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects

NCT00368979

Prostatic Hyperplasia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-interventional, observational and multicenter study. When subjects will be allowed the dutasteride and α-blocker orally once daily for two years by investigator's prescription. They will be invited to this observational study. All eligible subjects can be allowed the prior alpha blockers therapy. Details of acute urinary retention (AUR) and BPH-related prostatic surgery episodes will be recorded at every visit. Subjects will return to the clinic for assessment every 3 months until week 96. The efficacy and safety of combining the 5α-reductase inhibitor (5ARI), dutasteride, and the α-blocker will be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benign Prostatic Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males, age ≧ 50 years
* Clinical diagnosis of BPH by medical history and physical examination, including a digital rectal examination (DRE)
* IPSS score ≧ 8 points and prostate volume ≧ 30 mL
* Total serum PSA ≧ 4.0 ng/mL and ≦ 20 ng/mL at screening
* Previous TRUS-guided biopsy have been done with benign findings and with prostate cancer (CaP) not detected within the past 6 months.
* Dutasteride combination therapy will be allowed by investigator's prescription
* Ability to understand and willingly provide written informed consent

Exclusion Criteria

* History or evidence of prostate cancer and high grade prostatic intraepithelial neoplasia (HGPIN)
* With symptomatic urinary tract or prostate infection or urinary retention within 3 months prior to entry of study
* Use of finasteride within 6 months of screening visit
* Use of dutasteride within 12 months of screening visit

Minimum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No